Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy

Tr1X, Inc. announced the successful dosing of the first patient in the company’s TRX103-01 proof of concept trial for prevention of Graft versus Host Disease and improved outcomes in patients with hematologic malignancies undergoing mismatched hematopoietic stem cell transplantation.